COVID-19：Fujifilm在Avigan临床试验中确认有效性“：下个月申请批准
富士胶卷：
富士胶片宣布已在对COVID-19患者进行Avigan的临床试验中证实了某些功效。
下个月，我们将申请批准用作新型日冕病毒的治疗药物。
试验结果：
据Fujifilm称，这是一项对患者进行管理并旨在获得国家批准的临床试验。
该研究针对156位年龄在20至74岁之间的患者进行。
变成负面的时间：
检查症状改善和PCR试验结果阴性之前的时间，
该小组中的14.7天没有收到Avigan
治疗组11.9天
大约三天了。
安全问题：
此外，没有其他副作用，例如肾功能下降或肝功能下降。
没有安全隐患。
“ Avigan”临床试验：
最初计划于六月底。
但是，由于感染人数的减少，时间表被延长，审判继续进行。
NHK新闻
https://www3.nhk.or.jp/news/html/20200923/k10012630761000.html
Japanese Health Ministry Could Approve Favipiravir (Avigan) Before End of Year Targeting COVID-19
Japanese Health Ministry Acknowledges Potential Fast-Track
The drug was initially developed as a flu treatment by developer Fujifilm Toyama Chemical.
The sponsor initiated clinical trials back in March, which concluded recently.
Nikkei Asian Review reports that the study results are still under review,
but the prominent news platform reports that “…[T]he drug apparently has shown some effectiveness against coronavirus.”Apparently, the Japanese health ministry will fast-track approval should the data review turn out positive.
Recently, a ministry source quoted, “If the data from the clinical trials looks good, we could approve it in a month from when Fujifilm submits an application.”
The government, via the previous Prime Minister Shinzo Abe,
sought a fast-track previously but there was a lack of patient subjects.North American Activity
Sponsors of one kind or another are conducting at least 34 favipiravir-based clinical trials targeting COVID-19. In Canada,
Appili Therapeutics
is working on developing and commercializing the product for the North American market.Meanwhile, prestigious universities, such as Stanford, conduct favipiravir studies in the United States.
Fujifilm Toyama Chemical itself
is conducting a U.S.-based clinical trial (NCT04358549) scheduled for completion November 1, 2020.
Fujifilm Unit to Apply for Avigan Use for Coronavirus – JIJI PRESS
https://jen.jiji.com/jc/i?g=eco&k=2020092300630